On Apr. 27, 2020, Moderna announced it has submitted an Investigational New Drug application to the FDA for the companyﾒs mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2) to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases.